在LIBREXIA计划第三阶段的Milvexian剂量的推理
Jeffrey I Weitz1, Robert A Harrington2,
1Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada; Hamilton Health Sciences, Hamilton, Ontario, Canada.
新型XIa因子抑制剂Milvexian正在第三期试验中进行测试. 对心房,急性冠状动脉综合征和中风试验的剂量由第2阶段的结果决定,旨在获得更安全的抗凝剂.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 临床试验中的临床试验.
背景情况:
- 米尔维西安是一种口服的小分子抑制剂,向XIa因子 (FXIa).
- 与FXa.相比,FXIa正在作为潜在的更安全的抗凝剂点进行研究.
- 目前,Milvexian正处于临床开发的第三阶段.
研究的目的:
- 概述针对FXIa而不是FXa.的科学理由.
- 详细介绍一下米尔维克西安的药理学.
- 审查第二阶段试验结果,并为第三阶段的剂量策略提供信息.
主要方法:
- 这篇叙事综述综合了关于米尔维克西安发展的数据.
- 专注于在LIBREXIA计划中的第三阶段剂量方案的选择过程.
- 在LIBREXIA计划包括试验心房动 (AF),急性冠状动脉综合征 (ACS) 和中风.
主要成果:
- 第二阶段的结果指导了选择milvexian的第三阶段剂量.
- 针对不同的适应症选择了特定的剂量:100毫克两次用于AF,25毫克两次用于ACS和中风.
- 这些疗法将在LIBREXIA试验中对大约5万名患者进行评估.
结论:
- 选择的milvexian剂量旨在提供安全有效的抗凝剂.
- 第三阶段试验 (LIBREXIA AF,ACS,中风) 将验证这些疗法.
- 米尔维西安是一种有前途的新型口服抗凝剂,针对FXIa.
更多相关视频
09:12MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
Published on: December 21, 2011
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Dosage Regimens: Partial Pharmacokinetic Parameters
Dosage Regimen: Individualization
